The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down LSI Asia ’25 in Singapore and gear up for LSI Europe ’25 in London (September 7–11).

Accelus

Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants.

Aortyx

Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years.

Atraverse Medical

Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTWIRE™, its FDA-cleared transseptal access system. The funding will accelerate manufacturing, team expansion, and new product development, positioning Atraverse Medical to establish HOTWIRE as the next standard in left-heart access.

Augmedit

Announced the first closing of its Series A round to accelerate the global rollout of AI-driven augmented reality surgical software. Led by Egeria Impact Investments with participation from the EIC Fund, the raise supports commercialization in neurosurgery and expansion into new clinical specialties and markets.

Cognito Therapeutics

Reported positive results from the OVERTURE feasibility trial, demonstrating that Spectris AD significantly slows Alzheimer’s progression. The noninvasive neuromodulation therapy, which delivers gamma frequency light and sound, preserved cognitive function, daily activity, and brain volume in patients with mild-to-moderate Alzheimer’s disease.

Dilon Technologies

Received $9M in growth capital financing from JGB Management Inc. to accelerate operational scale-up and support continued double-digit revenue growth. The funding strengthens Dilon Technologies’ commercialization of its surgical portfolio, including HEMOBLAST BellowsⓇ, MarginProbeⓇ, and Navigator™ Gamma Probe product line.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-61325-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more